



ORDERING INFORMATION

To order PAVBLU™ (afibercept-ayyh), please refer to the list of distributors below. **PAVBLU™ is available in a single-dose pre-filled plastic syringe or single-dose glass vial.**



PRODUCT INFORMATION

	Product Description	NDC	Q-Code	Billing Unit
	PAVBLU™ (afibercept-ayyh) 2 mg/0.05 mL single-dose pre-filled plastic syringe	55513-056-01	Q5147	1 unit*
	PAVBLU™ (afibercept-ayyh) 2 mg/0.05 mL single-dose glass vial	55513-065-01	Q5147	1 unit*

*1 billing unit = 1 mg

DISTRIBUTOR LIST

Contact Information

PAVBLU™ 2 mg/0.05 mL single-dose pre-filled plastic syringe item

PAVBLU™ 2 mg/0.05 mL single-dose glass vial item

Besse Medical Ph: 800.543.2111 besse.com	10293945	10293955
BioCare Specialty Distribution Ph: 800.304.3064 biocare-us.com	1000974	1000972
Cardinal Health Specialty Hosp/Multi. Specialty Ph: 855.855.0708 PCP Ph: 877.451.3972 cardinalhealth.com	5951652	5951660
Cardinal Puerto Rico Ph: 787.625.4100 cardinalhealth.pr	5952502	5952494
CuraScript Specialty Distribution Ph: 877.599.7748 curascriptsd.com	10006159	10006158
McKesson Medical Surgical Ph: 866.625.2679 mms.mckesson.com	1261609	1261607
McKesson Plasma & Biologics Ph: 877.625.2566 mckesson.com	2994358	2994366
McKesson Specialty Health Ph: 415.983.8300 mckesson.com	5018905	501906
Metro Medical (Cardinal) Ph: 800.768.2002 metromedical.com	115601	116501

The specialty distributors identified can fill and distribute PAVBLU™ and are provided herein for informational purposes only and not as an endorsement or recommendation to use any particular pharmacy or distributor over another. This list may not be exhaustive and is subject to change. It represents no statement, promise, or guarantee by Amgen Inc. concerning coverage and/or availability of the product for any particular patient and it is the responsibility of the health care provider to determine the appropriate services provided to their patients.

Please see Indications and [Important Safety Information](#) and click here for [full Prescribing Information](#).



INDICATIONS

PAVBLU™ (aflibercept-ayyh) is indicated for the treatment of Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

- PAVBLU is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in PAVBLU.

WARNINGS AND PRECAUTIONS

- Intravitreal injections, including those with aflibercept products, have been associated with endophthalmitis and retinal detachments and, more rarely, retinal vasculitis with or without occlusion. Proper aseptic injection technique must always be used when administering PAVBLU. Patients and/or caregivers should be instructed to report any signs and/or symptoms suggestive of endophthalmitis, retinal detachment, or retinal vasculitis without delay and should be managed appropriately.
- Acute increases in intraocular pressure have been seen within 60 minutes of intravitreal injection, including with aflibercept products. Sustained increases in intraocular pressure have also been reported after repeated intravitreal dosing with VEGF inhibitors. Intraocular pressure and the perfusion of the optic nerve head should be monitored and managed appropriately.
- There is a potential risk of arterial thromboembolic events (ATEs) following intravitreal use of VEGF inhibitors, including aflibercept products. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause).
- The incidence of reported thromboembolic events in wet AMD studies during the first year was 1.8% (32 out of 1824) in the combined group of patients treated with aflibercept compared with 1.5% (9 out of 595) in patients treated with

ranibizumab; through 96 weeks, the incidence was 3.3% (60 out of 1824) in the aflibercept group compared with 3.2% (19 out of 595) in the ranibizumab group. The incidence in the DME studies from baseline to week 52 was 3.3% (19 out of 578) in the combined group of patients treated with aflibercept compared with 2.8% (8 out of 287) in the control group; from baseline to week 100, the incidence was 6.4% (37 out of 578) in the combined group of patients treated with aflibercept compared with 4.2% (12 out of 287) in the control group. There were no reported thromboembolic events in the patients treated with aflibercept in the first six months of the RVO studies.

ADVERSE REACTIONS

- Serious adverse reactions related to the injection procedure have occurred in <0.1% of intravitreal injections with aflibercept including endophthalmitis and retinal detachment.
- The most common adverse reactions ($\geq 5\%$) reported in patients receiving aflibercept were conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, and intraocular pressure increased.
- Patients may experience temporary visual disturbances after an intravitreal injection with PAVBLU and the associated eye examinations. Advise patients not to drive or use machinery until visual function has recovered sufficiently.

Please click here for full Prescribing Information for PAVBLU.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please visit PAVBLU.com for additional information and resources.

Call **800-77-AMGEN (800-772-6436)** if you have questions about the preparation and administration of PAVBLU™.

Reference: PAVBLU™ (aflibercept) Prescribing Information. Amgen.

PAVBLU™ is not indicated for Retinopathy of Prematurity, for which Regeneron has marketing exclusivity.